OncoPharm To Rechallenge, Or Not To Rechallenge
Oct 17, 2019
Dive into the complex world of immunotherapy rechallenge, where experts weigh the risks and benefits for patients with prior immune-related adverse events. Discover case studies that illuminate the importance of shared decision-making and careful patient monitoring. Explore strategies for managing lower-grade toxicity and the challenges faced during cancer treatment. With valuable insights into timing and management protocols, this discussion is vital for anyone interested in cutting-edge cancer care.
AI Snips
Chapters
Transcript
Episode notes
Deciding Re-challenge by AE Severity
- Assess immune-related adverse events by grade before deciding on immunotherapy re-challenge.
- Avoid re-challenge if it took a long time to taper corticosteroids and disease is controlled.
Unpredictable Adverse Event Recurrence
- About 50% of patients experience another immune-related adverse event upon immunotherapy re-challenge.
- The new adverse event may differ from the initial one, complicating prediction and management.
When to Consider Re-challenge
- Re-challenge if immune-related adverse events resolve quickly and disease progresses.
- Prefer single-agent immunotherapy for re-challenge over combination therapy to reduce risks.